MacroGenics (MGNX) Competitors

$4.07 +0.62 (+17.83%)

As of 02:55 PM Eastern

MGNX vs. MGTX, IVA, RLMD, GYRE, and BIOA

Should you buy MacroGenics stock or one of its competitors? MarketBeat compares MacroGenics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MacroGenics include MeiraGTx (MGTX), Inventiva (IVA), Relmada Therapeutics (RLMD), Gyre Therapeutics (GYRE), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry.

How does MacroGenics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MacroGenics has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	11.16	-$114.20M	-$1.42	N/A
MacroGenics	$149.50M	1.73	-$74.62M	-$1.17	N/A

MeiraGTx presently has a consensus price target of $25.67, indicating a potential upside of 161.64%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 35.30%. Given MeiraGTx's stronger consensus rating and higher probable upside, equities analysts clearly believe MeiraGTx is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

MacroGenics has a net margin of -49.91% compared to MeiraGTx's net margin of -140.31%. MacroGenics' return on equity of -120.19% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-140.31%	-1,065.47%	-53.33%
MacroGenics	-49.91%	-120.19%	-29.92%

In the previous week, MacroGenics had 10 more articles in the media than MeiraGTx. MarketBeat recorded 14 mentions for MacroGenics and 4 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.94 beat MacroGenics' score of 0.44 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MacroGenics beats MeiraGTx on 10 of the 17 factors compared between the two stocks.

How does MacroGenics compare to Inventiva?

Inventiva (NASDAQ:IVA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 197.23%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 35.30%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts plainly believe Inventiva is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

MacroGenics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	160.34	-$400.67M	N/A	N/A
MacroGenics	$149.50M	1.73	-$74.62M	-$1.17	N/A

Inventiva has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

In the previous week, MacroGenics had 12 more articles in the media than Inventiva. MarketBeat recorded 14 mentions for MacroGenics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat MacroGenics' score of 0.44 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva has a net margin of 0.00% compared to MacroGenics' net margin of -49.91%. Inventiva's return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
MacroGenics	-49.91%	-120.19%	-29.92%

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Inventiva beats MacroGenics on 10 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Relmada Therapeutics?

MacroGenics (NASDAQ:MGNX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

MacroGenics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

MacroGenics presently has a consensus target price of $5.50, indicating a potential upside of 35.30%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 62.47%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, MacroGenics had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 14 mentions for MacroGenics and 9 mentions for Relmada Therapeutics. MacroGenics' average media sentiment score of 0.44 beat Relmada Therapeutics' score of 0.20 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics has lower revenue, but higher earnings than MacroGenics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.73	-$74.62M	-$1.17	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A

Relmada Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -49.91%. MacroGenics' return on equity of -120.19% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-49.91%	-120.19%	-29.92%
Relmada Therapeutics	N/A	-157.81%	-135.88%

Summary

MacroGenics beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Gyre Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Gyre Therapeutics has higher earnings, but lower revenue than MacroGenics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$117.05M	5.85	$5.03M	-$0.09	N/A
MacroGenics	$149.50M	1.73	-$74.62M	-$1.17	N/A

In the previous week, Gyre Therapeutics and Gyre Therapeutics both had 14 articles in the media. MacroGenics' average media sentiment score of 0.44 beat Gyre Therapeutics' score of -0.13 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gyre Therapeutics has a net margin of -5.44% compared to MacroGenics' net margin of -49.91%. Gyre Therapeutics' return on equity of 3.13% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
MacroGenics	-49.91%	-120.19%	-29.92%

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 141.07%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 35.30%. Given Gyre Therapeutics' higher probable upside, research analysts plainly believe Gyre Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Gyre Therapeutics beats MacroGenics on 8 of the 15 factors compared between the two stocks.

How does MacroGenics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and MacroGenics (NASDAQ:MGNX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

BioAge Labs has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

MacroGenics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	80.49	-$80.61M	-$2.40	N/A
MacroGenics	$149.50M	1.73	-$74.62M	-$1.17	N/A

In the previous week, MacroGenics had 4 more articles in the media than BioAge Labs. MarketBeat recorded 14 mentions for MacroGenics and 10 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.73 beat MacroGenics' score of 0.44 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.9% of MacroGenics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MacroGenics has a net margin of -49.91% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
MacroGenics	-49.91%	-120.19%	-29.92%

BioAge Labs presently has a consensus price target of $45.00, suggesting a potential upside of 140.90%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 35.30%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

BioAge Labs and MacroGenics tied by winning 8 of the 16 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$258.37M	$7.98B	$6.29B	$12.48B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	-3.47	18.42	20.91	25.60
Price / Sales	1.73	7.71	548.78	75.41
Price / Cash	N/A	16.76	42.94	55.34
Price / Book	4.62	3.67	9.87	6.72
Net Income	-$74.62M	$223.05M	$3.55B	$333.73M
7 Day Performance	38.27%	-2.02%	-0.24%	0.38%
1 Month Performance	16.48%	3.03%	1.44%	4.02%
1 Year Performance	162.26%	1.98%	41.01%	36.37%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	2.0556 of 5 stars	$4.07 +17.8%	$5.50 +35.3%	+124.0%	$258.37M	$149.50M	N/A	430	News Coverage Earnings Report Analyst Revision Gap Up High Trading Volume
MGTX MeiraGTx	3.2194 of 5 stars	$9.76 +0.6%	$25.67 +163.0%	+93.6%	$792.47M	$81.39M	N/A	300	Earnings Report
IVA Inventiva	2.8088 of 5 stars	$5.40 +2.4%	$16.56 +206.9%	+54.7%	$787.55M	$5.07M	N/A	100	Gap Up
RLMD Relmada Therapeutics	2.8186 of 5 stars	$7.32 -1.3%	$12.00 +64.0%	+1,820.5%	$763.60M	N/A	N/A	10	News Coverage Earnings Report
GYRE Gyre Therapeutics	2.3281 of 5 stars	$7.73 -2.5%	$17.00 +120.1%	-36.7%	$752.19M	$116.59M	776.28	40	Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. MGTX, IVA, RLMD, GYRE, and BIOA

How does MacroGenics compare to MeiraGTx?

Summary

How does MacroGenics compare to Inventiva?

Summary

How does MacroGenics compare to Relmada Therapeutics?

Summary

How does MacroGenics compare to Gyre Therapeutics?

Summary

How does MacroGenics compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. MGTX, IVA, RLMD, GYRE, and BIOA

How does MacroGenics compare to MeiraGTx?

Which has more risk and volatility, MGTX or MGNX?

Do institutionals & insiders have more ownership in MGTX or MGNX?

Which has better earnings & valuation, MGTX or MGNX?

Do analysts rate MGTX or MGNX?

Is MGTX or MGNX more profitable?

Does the media refer more to MGTX or MGNX?

Summary

How does MacroGenics compare to Inventiva?

Do analysts recommend IVA or MGNX?

Which has stronger valuation and earnings, IVA or MGNX?

Which has more volatility & risk, IVA or MGNX?

Does the media refer more to IVA or MGNX?

Is IVA or MGNX more profitable?

Do insiders and institutionals have more ownership in IVA or MGNX?

Summary

How does MacroGenics compare to Relmada Therapeutics?

Which has more risk and volatility, MGNX or RLMD?

Do analysts prefer MGNX or RLMD?

Do insiders & institutionals believe in MGNX or RLMD?

Does the media favor MGNX or RLMD?

Which has preferable earnings & valuation, MGNX or RLMD?

Is MGNX or RLMD more profitable?

Summary

How does MacroGenics compare to Gyre Therapeutics?

Which has more risk and volatility, GYRE or MGNX?

Which has preferable valuation & earnings, GYRE or MGNX?

Does the media favor GYRE or MGNX?

Do institutionals & insiders have more ownership in GYRE or MGNX?

Is GYRE or MGNX more profitable?

Do analysts recommend GYRE or MGNX?

Summary

How does MacroGenics compare to BioAge Labs?

Which has more volatility and risk, BIOA or MGNX?

Which has higher earnings and valuation, BIOA or MGNX?

Does the media refer more to BIOA or MGNX?

Do insiders and institutionals have more ownership in BIOA or MGNX?

Is BIOA or MGNX more profitable?

Do analysts rate BIOA or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools